Semaglutide vs GLP-2 T: A Research Comparison Guide

Semaglutide and tirzepatide differ in one structural respect that determines everything else about them: how many receptors each engages. Semaglutide is a single agonist. Tirzepatide is a dual agonist. In this catalogue they are listed under coded designations — GLP1 S and GLP2 T respectively — and this page states that mapping plainly so researchers searching either name land in the right place.

What is the difference between semaglutide and tirzepatide?

Receptor targets. Semaglutide engages the GLP-1 receptor. Tirzepatide engages GLP-1 and GIP. That is the whole structural distinction, and every other difference between them — sequence, molecular weight, the shape of the published literature — follows from it.

What this page will not do is tell you which is better. That depends entirely on what is being investigated, and a catalogue page is the wrong place to settle it. The primary-literature searches at the foot of this page return the actual work, including studies that cut against whichever framing a reader arrived with.

Why are they listed as GLP1 S and GLP2 T?

Because listings here use coded designations for compounds in this class, and the number in the code records how many receptors the compound engages. GLP1 S is the single agonist. GLP2 T is the dual. Retatrutide — the triple — is GLP3 R.

Researchers searching “semaglutide vs tirzepatide” and finding coded listings are usually trying to confirm they are looking at the right material. This is that confirmation.

What does “compounded” semaglutide or tirzepatide mean?

Compounding is a pharmacy activity: preparing a formulation to order under a pharmacist’s licence. It is a regulated practice with its own rules, and it is not what a research-chemical supplier does.

Material listed here is neither compounded nor a compounded product. It is characterised research material supplied lyophilised, with a per-batch certificate, for in-vitro laboratory use. If a search for “compounded semaglutide” brought you here, the honest answer is that this is a different category of thing, and the distinction matters legally as well as practically.

What do they cost, and how should the comparison be made?

Semaglutide lists at $50 and tirzepatide at $70. As with every peptide, the meaningful comparison is per milligram, and that requires knowing the fill weight — two vials at the same price are not comparable if one holds twice the material. Each product page states its fill weight; the reconstitution calculator converts weight and diluent volume into concentration and units per syringe mark.

A price far below the category is a question rather than a bargain. These are long synthetic sequences, and length is where cost and failure risk both come from.

What should the certificate show for either one?

Mass confirmation first. For peptides of this length the realistic failure is a truncated or wrong sequence — material that is still a peptide, still passes a generic purity assay, and is still not what the label says. Purity answers “how much of this vial is one substance”. Mass answers “is that substance the one named”. Only the second is a question about identity.

Then fill quantity, then the analytical method stated rather than implied: “99.2% by RP-HPLC at 214nm” is a measurement, “>99% purity” is a claim. And check the certificate names the batch on your vial — a certificate naming no batch is a specimen, establishing that a laboratory once tested some material rather than that it tested yours. Every batch sold here publishes its certificate on the test results page.

How do they sit against the rest of this catalogue?

Apart from each other and GLP3 R, nothing else stocked here is in this class. Tesa-morelin and Ipamorelin act on the pituitary. MOTS-C and SS31 – 10mg are mitochondrially associated. BPC-157 and TB-500 are fragments of larger proteins. GHK-Cu (Copper Peptide) is a copper-coordinated tripeptide. Comparisons across those groups are category errors, however often they are made.

Why receptor count is a design choice and not a ranking

It is tempting to read single → dual → triple as a straight line of increasing capability, and the naming here invites that reading. It should be resisted. Adding a receptor target adds a mechanism to characterise, not automatically a better outcome, and the interaction between targets is itself a research question rather than a settled fact.

What the count does reliably predict is complexity. A single-target compound has one pathway to attribute an observation to. A dual agonist has two, plus whatever their interaction contributes. A triple has three. For research design that is a cost, not a feature: the more targets a compound engages, the harder it is to say which one produced what you measured. Researchers choosing between these are usually choosing how much attribution they are willing to give up, and that is a decision about experimental design rather than about potency.

The same logic runs through the blends in this catalogue. A fixed multi-component preparation buys convenience and a discount at the price of never being able to attribute a result to one component. Multi-agonist peptides pose the same trade in molecular form.

What the coded naming does and does not tell you

The codes are inventory labels. GLP1 S, GLP2 T and GLP3 R record receptor count and nothing else — not purity, not source, not quality. A listing under a coded name is not evidence of anything in either direction, and a supplier using plain names is not thereby more trustworthy.

What is evidence is checkable and short: does the supplier publish a certificate per batch rather than a single specimen; does that certificate name the analytical method; does it report mass as well as purity; does it state fill quantity. Those four questions can be asked of any listing, under any naming convention, and they separate suppliers far more reliably than how a product is labelled.

This matters here specifically because coded listings are common across this market and are frequently read as evasive. The mapping on this page exists so that a researcher who wants the plain name has it, and can then go and ask the four questions that actually matter.

Vial sizing and what it does to the arithmetic

Reconstitution volume is set by the concentration you want, not by the compound, and the same volume produces different concentrations from different fill weights. A 10mg vial reconstituted with 2mL gives 5mg/mL; a 5mg vial with the same 2mL gives 2.5mg/mL. Carrying a volume across from another compound without re-checking the fill weight is the most common arithmetic error in this whole category, and it happens after every calculator has finished its job.

The second-order consideration is exposure time. A concentration that takes a month to consume exposes reconstituted material for a month, and peptides in solution are markedly less stable than as dry powder. Matching the volume to the pace of the work costs nothing and removes an entire class of degradation problem.

Reconstitution and handling

Both ship lyophilised and tolerate ambient transit; store cold and dark long-term. Bring a vial to room temperature before the stopper is pierced, because solvent entering a cold vial invites condensation. Reconstitute with Bacteriostatic Water where more than one withdrawal is planned — the benzyl alcohol preservative is the entire reason to prefer it over sterile water — adding diluent down the vial wall rather than onto the lyophilised cake, and swirling rather than shaking.

In solution both are markedly less stable than as dry powder. Match the reconstitution volume to how quickly the vial will actually be consumed. Full method: bacteriostatic water for research peptides.

Frequently asked questions

Where to read the primary literature

Live searches against the two public registries, not curated citations.

• PubMed: semaglutide · ClinicalTrials.gov
• PubMed: tirzepatide · ClinicalTrials.gov
• PubMed: GIP receptor agonist

All materials listed are supplied strictly for in-vitro laboratory and research use. They are not drugs, foods or cosmetics, are not for human or veterinary use, and nothing on this page describes an intended use in humans. Figures quoted are catalogue list prices at the time of writing.